TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04074798

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: assessment of hyperventilation, postural control and psychological behavior
Description: assessment of hyperventilation, postural control and psychological behavior

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: assessment of hyperventilation, postural control and psychological behavior
Description: assessment of hyperventilation, postural control and psychological behavior
Study: NCT04731909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg,ivgtt,d1,q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12 mg/d,d1-14,q3w,4-6 cycles in total. In maintenance treatment period, Anlotinib 12 mg/d,d1,Oral for 2 weeks and stop for 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2,d1,q3w,4-6 cycles in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5,d1,q3w,4-6 cycles in total.
Study: NCT04504097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: m-Health
Description: Participants receive a weekly bidirectional text message (SMS) asking how they are doing. They are requested to reply fine, or not fine, in which case they will be contacted with support by a peer navigator. If they do not reply to the message within the specified timeframe a peer navigator will follow up with them.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV self-testing
Description: Participants will receive HIVST kits so that they can perform their HIV testing.
Study: NCT03756558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-Seal System
Description: Use of the Cross-Seal system to close the femoral arteriotomy
Study: NCT04504097

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Description: Participants will receive HIVST kits so that they can perform their HIV testing.
Study: NCT02575599

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided self-determination programme (GSD)
Description: The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
Study: NCT02965560

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.
Study: NCT01976663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVEDERM VOLIFT® XC
Description: Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
Study: NCT01810393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
Study: NCT03199846

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT00445458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT04097132

Intervention type: DEVICE
Intervention: echocardiography
Description: echocardiography for left atrial diameter, size ,Ejection Fraction Holter for detection of paroxusmal AF
Study: NCT03794089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief anxiety intervention
Description: Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual PC-MHI care
Description: Anxiety treatment with mental health provider in local primary care clinic
Study: NCT03888144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5 mg of oxycodone taken by mouth every 6 hours for 5 days
Study: NCT00445458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT03888144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 10 mg of ketorolac taken by mouth every 6 hours for 5 days
Study: NCT01045447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
Study: NCT03464786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lando® absorbable collagen membrane
Description: Subjects who are fit for the study will be randomized to either intervention arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Geistlich Bio-Gide resorbable bilayer membrane
Description: Subjects who are fit for the study will be randomized to either intervention arms.
Study: NCT02629380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: meniscectomy alone
Description: The patients randomized in this group will receive arthroscopic meniscectomy alone
Study: NCT00535301

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: grafted anterior prolapse repair
Description: anterior vaginal prolapse repair with graft
Study: NCT01016730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01045447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Study: NCT01438411

Intervention type: DRUG
Group type: OTHER
Intervention: Cholic Acid
Description: 10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
Study: NCT00004867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT02092948

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [124I] PSCA-Minibody PET/CT imaging of the whole body
Description: Whole body Imaging
Study: NCT02673658

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor + problem solving
Description: Developmental motor tasks incorporating cognitive concepts such as object permanence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: body weight support training
Description: Mobility tasks to change positions or move the body with assistance to initiate movement
Study: NCT03738865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen
Description: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-Pen
Description: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novo Glucagon
Description: 1 mg subcutaneous injection of Novo Glucagon (glucagon injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novo Glucagon
Description: 1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
Study: NCT00535301

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sutured anterior vaginal prolapse repair
Description: anterior vaginal prolapse repair with suture
Study: NCT01955031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: A telemonitoring program with educational tools is given to people with type 2 diabetes at their home. It is composed of three softwares to improve eating habits available on touchpad, a self-monitoring blood glucose device, a balance to measure weight and fat mass, and a pedometer to evaluate physical activity. Data are securely sent and stored into a web service which delivers a synthesis to patients and health professionals.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists who take part into the Regional Health Network in Diabetes DIAMIP. If patients accept to participate to the study and sign up the protocol consent, they are given questionnaires about nutrition, physical activity and quality of life. A dietician analyses with each patient the results of a food inquiry. Patients are randomised into two groups: one arm is trained to the telemonitoring program before receiving it at home, and the other arm follows usual care. During 12 months, the telemonitoring group uses the device. The investigators (GP or diabetologists) can use the specific secured website to follow the measured parameters and to make appropriate decisions about health care of their patient. No consultation are scheduled in advance.
Study: NCT03121989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized Pyruvate (13C) Injection
Description: The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coil Testing
Description: Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that will act as a test object. The test object provides a signal that will be used to ensure that the MRI system is functioning properly for participants in Group 2 . The plastic ball does not come in contact with you and there are no known risks associated with it.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NAC
Description: Participants will be receiving NAC as part of their clinical treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC
Description: Participants will be receiving NAC as part of their clinical treatment.
Study: NCT02305329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Study: NCT02623062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Sodium Alginate Oral Suspension sachet
Description: Contents of 2 sachets taken four times daily for 7 days
Study: NCT02305329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Study: NCT00358670

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: infliximab
Description: Infliximab maintenance therapy~intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: Infliximab intermittent therapy:~Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 \[NCT00251641\] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a \>=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse.
Study: NCT01834365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured education
Description: Formatted education about hypertension
Study: NCT02623062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Contents of 2 sachets taken four times daily for 7 days
Study: NCT04067856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection
Description: Intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection
Description: Intravitreal injection
Study: NCT01834365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured education
Description: Formatted education about hypertension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without structure education with checklist
Study: NCT03582306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High chlorophyll diet - intervention 1st
Description: Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High chlorophyll diet - control 1st
Description: Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
Study: NCT02660359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study: NCT00875394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 100 mg Once a day (QD) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: metformin
Description: metformin 850 mg Twice a day (BID) for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin
Description: metformin 850 mg Twice a day (BID) for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin
Description: metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Antidiabetic Standard of Care
Description: Patient can take any oral antidiabetic drug (other than metformin)
Study: NCT04440111

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One year training
Description: At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015.~After that, they will make a practical workshop on BLS. Finally they will repeat the initial test. The second year, this group will only make the test, they won't receive any theory or practice.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Two years training
Description: At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015. After that they will make a practical workshop on BLS.~Finally they will repeat the initial test. The second year, this group will repeat the same process.
Study: NCT00119444

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periacetabular osteotomy
Description: osteotomy of the pelvis to increase acetabular coverage
Study: NCT04100226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1.25 (OH)2 cholecalciferol)
Description: Vitamin D 3 in a dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for Vitamin D deficient interstitial lung disease patients and every month for 3 months for vitamin D insufficient interstitial lung disease patients.~calcium supplementation in form of ca carbonate 600 mg oral capsule once daily for 3 months for all patients.
Study: NCT04596163

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus thoracis muscle plane block
Description: After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus thoracis muscle plane block
Description: After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.
Study: NCT02677545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study: NCT04537091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rESWT
Description: rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography.
Study: NCT01100177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5mg/m2/d

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy (60Gy) 2 Gy per day during 30 days
Study: NCT02528201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200 milligrams
Description: Celecoxib 200 milligrams once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 400 milligrams
Description: Celecoxib 400 milligrams once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac 50 milligrams
Description: diclofenac 50 milligrams three times a day